Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Platinum-Resistant Recurrent Ovarian Cancer Patients

October 2, 2012 Astex Pharmaceuticals to Present at BIO Investor Forum DUBLIN, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that James S.J. Manuso, PhD, chairman and chief executive officer, will present at BIO Investor Forum on Tuesday, October 9th in San Francisco. The Company's presentation will begin at 11:30 a.m. PT. A live webcast of the presentation will be available in the Investor Events section of the Company's website, www.astx.com. The webcast will be archived for 30 days. About Astex Pharmaceuticals Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de -risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen ® (decitabine) for Injection and receives significant royalties on global sales. For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com. CONTACT: Timothy L. Enns Astex Pharmaceuticals, Inc. Senior Vice President Corporate Communications & Marketing Tel: +1 (925) 560-2810 E-mail: [email protected] Alan Roemer The Trout Group Managing Director Tel: +1 (646) 378-2945 E-mail: [email protected] Susanna Chau Astex Pharmaceuticals, Inc. Manager Investor Relations Tel: +1 (925) 560-2845 E-mail: [email protected] Kari Watson MacDougall Biomedical Communications Senior Vice President Tel: +1 (781) 235-3060 E-mail: [email protected]

The release as fetched from its publisher. astx.com ↗